Picture supply: The Motley Idiot.
Novo Nordisk (NVO 9.01%)
Q3 2022 Earnings Name
Nov 02, 2022, 8:00 a.m. ET
Contents:
- Ready Remarks
- Questions and Solutions
- Name Members
Ready Remarks:
Operator
Good day, and thanks for standing by. Welcome to Q3 2022 Novo Nordisk A/S earnings convention name. [Operator instructions] I might now like handy the convention over to your speaker right now, CEO, Lars Fruergaard Jorgensen. Please go forward.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Thanks, operator. Welcome to this Novo’s earnings name for the primary 9 months of 2022 and the outlook for the yr. My identify is Lars Fruergaard Jorgensen, and I am the CEO of Novo Nordisk. With me right now, I’ve govt vice chairman and head of economic technique and company affairs, Camilla Sylvest; govt vice chairman and head of North America operations, Doug Langa; govt vice chairman and head of growth, Martin Holst Lange; and at last, chief monetary officer, Karsten Munk.
All of us shall be obtainable for the Q&A session. At this time’s announcement and the slides for this name can be found on our web site, novonordisk.com. Please be aware that the decision could be webcast stay, and a recording shall be made obtainable on our web site as properly. Name is scheduled to final for one hour.
Please flip to the subsequent slide. The presentation is structured as outlined on Slide 2. Please be aware that each one gross sales and working revenue statements shall be at fixed change charges, except in any other case specified. The Q&A session will start in about 25 minutes.
Please flip to Slide 3. As all the time, I must advise you that this name will comprise forward-looking statements. These are topic to dangers and uncertainties that might trigger precise outcomes to vary materially from expectations. For additional data on the danger elements, please see the corporate’s filings for the primary 9 months of 2022 and the slides ready for this presentation.
Please flip to the subsequent slide. Within the first 9 months of 2022, we delivered double-digit gross sales and working revenue development, which has enabled us to lift our outlook for the complete yr. I wish to begin this name by going by way of the efficiency highlights throughout our operations earlier than handing over the phrase to my colleagues. We proceed to make progress throughout all dimensions of service and sustainability.
Our carbon emissions decreased by 18% in comparison with the primary 9 months of 2019, and we proceed to achieve much more sufferers in comparison with the identical interval final yr. Inside our aspiration of being a sustainable employer, we expanded the variety of ladies in senior management positions to 38% in comparison with 36% by the tip of September 2021. Inside R&D, we’re happy with the encouraging part 2 information with CagriSema in Sort 2 diabetes, in addition to the profitable completion of the pivotal part 3 program for once-weekly insulin icodec. Each help our aspiration of additional elevating the innovation bar for diabetes therapies.
Martin will come again to this and all our R&D milestones later on this name. Within the first 9 months of 2022, we delivered double-digit gross sales development, reflecting stable industrial execution throughout geographies and our remedy areas. Whereas each working models contributed to gross sales development, we noticed specific robust gross sales development in North America, pushed by accelerated demand for our GLP-1 therapies. This has enabled us to extend the outlook for the yr.
Camilla and Doug will undergo the small print per remedy space later. Lastly, Karsten will undergo the monetary particulars, however I am very happy with our gross sales development of 16% and working revenue development of 14% within the first 9 months of 2022. With that, I will now give the phrase to Camilla for an replace on industrial execution.
Camilla Sylvest — Govt Vice President, Head of Industrial Technique and Company Affairs
Thanks, Lars. And please flip to the subsequent slide. As final talked about, our 16% gross sales development within the first 9 months of 2022 was pushed by each working models, with North America operations rising by 22% and worldwide operations rising by 11%. Our GLP-1 gross sales elevated 44% by North America rising 39% and worldwide operations rising 55%.
Insulin gross sales decreased by 11%, pushed by a 7% decline in worldwide operations and a 20% gross sales declines in North America operations. The U.S. insulin gross sales declined by 22%, pushed by decrease realized costs and a decline in quantity. Insulin gross sales and worldwide operations have been impacted by the implementation of volume-based procurement in China from Might 22, in addition to decrease gross sales in EMEA.
Weight problems care gross sales grew 75 total, and worldwide operations prolonged gross sales grew 73%. And in North America operations, weight problems care gross sales grew 77%. Within the U.S., weight problems care gross sales grew 81%. Uncommon illness gross sales grew 2%, pushed by a 4% gross sales improve in worldwide operations, offset by a 3% decline in North America operations.
Please flip to Slide 6. Our 14% gross sales development inside diabetes care is quicker in all diabetes market. Meaning now we have improved our market share by 1.7 share factors to 31.6%. We proceed to be on monitor to achieve one-third of the diabetes worth market by 2025.
This improve primarily displays GLP-1 market development, in addition to share positive aspects in each working models. And please flip to the subsequent slide. In worldwide operations, diabetes care gross sales elevated by 9% within the first 9 months of ’22, pushed by GLP-1 gross sales that grew by 55%. Novo Nordisk stays the market chief in worldwide operations, with a GLP-1 worth market share of 69.6%.
That is pushed by share positive aspects throughout geographies. Ozempic continues to develop its GLP-1 market share management in worldwide operations with a 41.3% market share. Whereas the GLP-1 class is rising greater than 40%, GLP-1 penetration stays low at round 4% of whole diabetes teams globally. And with that, I’ll hand over the phrase to Doug.
Doug Langa — Govt Vice President, Head of North America Operations
Thanks for that replace, Camilla. Please flip to the subsequent slide. The U.S. GLP-1 market quantity grew by greater than 40%, evaluating the third quarter of 2022 to the third quarter of 2021, with once-weekly injectable GLP-1s and Rybelsus as the primary drivers.
The current competitor launch in GLP-1 has supported the continued acceleration in market development from an NBRx perspective, in addition to all-time excessive ranges for our portfolio GLP-1 merchandise throughout Q3. Measured on whole prescriptions, Novo Nordisk has maintained its market management with a 52.4% market share. Moreover, Ozempic continues to be the market chief with a 38.7% TRx market share. Rybelsus continues to develop and has now been launched in 43 nations.
Within the first 9 months of 2022, it was the second largest contributor to development in Novo Nordisk after Ozempic. Please go to the subsequent slide. Weight problems care gross sales elevated by 75%, with 77% development in North American operations and 73% in worldwide operations. Moreover, the worldwide weight problems market enlargement continues with a quantity development of the worldwide branded weight problems market of greater than 60%.
We proceed to be inspired by the efficiency of Saxenda in worldwide operations. Area EMEA is a key development driver with 96% development within the first 9 months of 2022. Particularly, the expansion continues to be notably robust in nations which have some degree of reimbursement, such because the U.Okay., Norway, and Israel. Within the U.S., weight problems care gross sales grew by 81%, with each Wegovy and Saxenda contributing to development.
Following the beforehand introduced Wegovy provide points within the U.S., our focus stays to proceed continuity of care to the sufferers which have already initiated therapy. In step with expectations, this has negatively impacted Wegovy prescription tendencies. Positively, Saxenda prescription tendencies have accelerated and proceed to be at all-time excessive ranges. Concerning Wegovy provide, we count on to make all doses of Wegovy obtainable within the U.S.
in December. We plan to provoke broad industrial actions to start with of 2023. Now, again over to Camila for an replace on uncommon illness.
Camilla Sylvest — Govt Vice President, Head of Industrial Technique and Company Affairs
Thanks, Doug. Subsequent slide, please. Our uncommon illness gross sales elevated by 2% within the first 9 months of 2022. This was pushed by a 4% gross sales development in worldwide operations, offset by a 3% decline in North America operations.
Uncommon blood issues grew by 6%, pushed by NovoSeven, in addition to the launch merchandise, Esporect and Refixia. Particularly, haemophilia A merchandise grew by 6%, haemophilia B gross sales by 9%, and NovoSeven by 6%. Uncommon endocrine dysfunction gross sales declined by 6%. The declining gross sales have been pushed by worldwide operations reducing 2% and by North America operations reducing by 13%.
The gross sales have been negatively impacted by decrease realized costs within the U.S. And now, over to you, Martin, for an replace on R&D.
Martin Holst Lange — Govt Vice President and Head of Growth
Thanks, Camila. Please flip to Slide 11. In August, we shared the thrilling information from the part 2 trial for CagriSema in folks with Sort 2 diabetes. I wish to briefly stroll by way of these outcomes.
This was a 32-week trial that investigated the efficacy and security of our fastened dose mixture of CagriSema in comparison with the person elements of Semaglutide 2.4 milligram and cagrilintide 2.4 milligram. All merchandise have been administered as soon as weekly. The trial included 92 folks with Sort 2 diabetes and chubby. And other people have been equally randomized among the many free therapy arms.
Within the trial, the imply baseline A1c was 8.4%. And the imply baseline physique weight was 106 kilograms. After 32 weeks of therapy, folks handled with CagriSema achieved a numerically larger A1c of two.18 share level in comparison with a discount of 1.79 share factors for folks handled with Semaglutide and 0.93 share level for folks handled with cagrilintide alone. Folks handled with CagriSema had numerically larger physique weight discount of 15.6% in comparison with a discount of 5.1% for folks handled with Semaglutide and eight.1% for folks handled with cagrilintide alone.
Within the trial, CagriSema appeared to have a protected and well-tolerated profile. Total, these outcomes point out that CagriSema reduces blood sugar greater than the 2 motor elements alone. And the load loss seen within the trial confirms the substantial weight decreasing potential of CagriSema. Primarily based on the outcomes, potential initiated from this system [Technical Difficulty] in folks with Sort 2 diabetes through the course of 2023.
Subsequent slide, please. ONWARDS 5 was a 52-week efficacy and security trial, once-weekly insulin icodec to once-daily basal insulin. This was both insulin degludic or insulin glargine. The trial included 1,085 insulin-naive folks with Sort 2 diabetes.
The first goal of the trial was to show noninferiority of insulin icodec in comparison with once-daily basal insulin analogs in lowering A1c at 52 weeks. ONWARDS 5 included a dose-guided, in addition to real-world proof, reminiscent of substantial [Technical Difficulty] in comparison with the opposite ONWARDS trials. Altogether, we consider that this design will improve your understanding and dialogue of how insulin icodec might make a distinction for sufferers in an precise scientific apply setting. This trial was a [Inaudible] trial, and it achieved its main endpoint by demonstrating noninferiority in lowering hemoglobin A1c at week 52 with the insulin icodec as in comparison with once-daily basal insulin analogs.
From an total baseline A1c of 8.9%, once-weekly insulin icodec achieved a superior discount in estimated A1c of 1.68% in comparison with 1.31% for once-daily insulin analog with an estimated therapy distinction of 0.38 share factors. As well as, we introduced the charges of extreme and clinically vital hypoglycemia. Within the trial, once-weekly insulin icodec seem to have a protected and well-tolerated profile. In conclusion, we’re very happy to share the optimistic outcomes from the ONWARDS 5 trial.
These outcomes verify the info studying within the beforehand reported ONWARDS program. The outcome highlighted that insulin icodec has the potential to be a really perfect starter insulin for folks with Sort 2 diabetes, in addition to a really enticing choice together with mealtime insulin as proven in ONWARDS 4, thus masking the complete spectrum of Sort 2 diabetes. We count on the submitting for regulatory approval of once-weekly insulin icodec within the U.S., within the EU, and in China through the first half of 2023. Are you able to flip to the subsequent slide? In September, we accomplished the 24-week foremost a part of the part 3 trial with concizumab that with the explorer8 in folks with haemophilia A or haemophilia B with out inhibitors.
The trial met its main endpoint, confirming superiority of concizumab prophylaxis therapy in comparison with no prophylaxis therapy in lowering the annual bleeding price in each haemophilia A or haemophilia B sufferers with out inhibitors. The secondary confirmatory endpoint of demonstrating noninferiority of concizumab prophylaxis as in comparison with earlier prophylaxis issue therapy in lowering the API was not met. Within the trial, concizumab appeared to have a protected and well-tolerated profile with no thromboembolic occasions reported after the therapy restart following the therapy pause. Primarily based on the outcomes of explore8, we’re assessing additional growth actions and timing of regulatory submissions in folks with out inhibitors.
Now, staying inside uncommon illness, I am very excited to share that therapy has been initiated within the first Mim8 part 3a trial in haemophilia A. That is known as FRONTIER 2. Primarily based on the outcomes we noticed in part 1 and a couple of, now we have very excessive expectations for the trial and the distinction that Mim8 make for sufferers with haemophilia A in managing their illness. Moreover, now we have submitted the doc for regulatory approval within the U.S.
for the therapy of main hyperoxaluria. The doc was a part of the Dicerna Prescribed drugs acquisition we made again in 2021. Inside different critical continual illnesses, now we have accomplished a 12-week part 2 trial of oral PCSK9 in 267 folks with a ASCVD or threat of a ASCVD. The trial met its pipeline by demonstrating superiority versus placebo, enduring low-density lipoprotein ldl cholesterol, and appeared to have a protected and well-tolerated profile.
Nonetheless, resulting from industrial and portfolio issues, the event of oral PCSK9 shall be terminated. Now, let’s flip to the opposite high-level R&D milestones that I didn’t cowl within the earlier slides. Inside diabetes, now we have initiated a part 1 trial with once-weekly oral Semaglutide, in addition to a part 2 trial with larger doses of Ozempic within the third quarter of this yr. The latter is a 49-week trial investigating the efficacy and tolerability of 8 and 16 milligram of Ozempic, respectively.
The trial is predicted to incorporate round 240 folks with Sort 2 diabetes. Additional, within the first half of 2023, we count on outcomes from the at present ongoing part 3 trial will oral semaglutide 25 and 15 milligrams, respectively. Lastly, inside weight problems, we’re very excited to have initiated the part 3a trial known as REDEFINE 1 for CagriSema. REDEFINE 1 is a 68-week trial, evaluating the efficacy and security of once-weekly CagriSema with semaglutide 2.4 milligram, cagrilintide 2.4 milligram, and placebo.
The trial is predicted to enroll roughly 3,400 folks with weight problems or chubby and comorbidities, and is the primary pivotal trial within the REDEFINE market. Additional, through the first half of 2023, we count on outcomes from the part 3a trial with all semaglutide 50 milligram, in addition to the part 1/2 trial outcomes from the continued trial with PYY. Altogether, we’re wanting very a lot ahead to an thrilling interval with scientific trial initiations, in addition to outcomes throughout different areas. With that, over to you, Karsten.
Karsten Munk Knudsen — Chief Monetary Officer
Thanks, Martin. Please flip to the subsequent slide. Within the first 9 months of 2022, our gross sales grew by 26% in Danish kroner and 16% at fixed change charges, pushed by each our working models. The gross margin elevated to 84.3% to 83% in 2021, pushed by a optimistic product combine resulting from elevated GLP-1 gross sales, a optimistic foreign money impression of 0.9 share factors, and productiveness enhancements.
These results are countered by lower-realized costs within the U.S. and China. Gross sales and distribution prices elevated by 28% in Danish kroner and 19% at fixed change charges. The rise is pushed by launch actions and promotional spend for Rybelsus and Ozempic, in addition to market growth actions for weight problems.
The fee improve is reflecting low exercise ranges in 2021 resulting from COVID-19, in addition to larger distribution prices. Analysis and growth prices elevated by 31% in Danish kroner and 26% at fixed change charges. The rise is pushed by larger scientific exercise ranges inside different critical continual illnesses and GLP-1, in addition to the working prices and amortization associated to the acquisition of Dicerna Prescribed drugs within the fourth quarter of 2021. Administration prices elevated by 9% in Danish kroner and 5% at fixed change charges.
Working revenue elevated by 28% in Danish kroner and by 14% at fixed change charges. Web monetary objects for 2022 confirmed a lack of round 5 billion kroner in comparison with a achieve of round 1 billion in 2021. This primarily pertains to losses following the appreciation of the U.S. greenback as mirrored within the favorable foreign money impression in working revenue.
The efficient tax price for the primary 9 months of 2022 was 20.5% in comparison with 19.8% in 2021. Web revenue elevated by 14%, and diluted earnings per share elevated by 15% to 18.42 kroner. Free money circulation was 62.5 billion Danish kroner in comparison with 52.3 billion Danish kroner in ’21. The money conversion within the first 9 months of 2022 is positively impacted by timing of rebate funds within the U.S., together with provisions associated to the revised 340B distribution coverage.
Revenue underneath the 340B program has been partially acknowledged. We proceed 2022 with a stable development momentum and now count on the gross sales development to be between 14% and 17% at fixed change charges. That is based mostly on quite a lot of assumptions as described within the firm bulletins. The raised steerage displays expectations for gross sales development in each worldwide operations and North America operations and throughout remedy areas, however primarily pushed by diabetes and weight problems care.
The up to date steerage is predicated on the expectation that each one the [Inaudible] can be found within the U.S. towards the tip of the yr. The outlook displays that we count on continued periodic provide constraints and associated drug scarcity notifications. That is pushed by higher-than-expected quantity development for GLP-1-based merchandise, reminiscent of Ozempic, and non permanent capability limitations at some manufacturing websites.
We’re step by step rising our provide capability and count on this to be adequate to help a possible continuation of the present gross sales development trajectory. We now count on that working revenue will develop between 13% and 15% at fixed change charges as this primarily displays the gross sales development outlook and continued investments in present and future development drivers. We’re additionally allocating extra assets to each early and late-stage R&D pipeline actions. As talked about earlier than, our acquisition of Dicerna Prescribed drugs is negatively impacted, impacting working revenue development by round 2 share factors resulting from larger working prices and amortization of intangible belongings.
Given the present change charges, most notably strengthening of the U.S. greenback, we count on a optimistic foreign money impression for 2022, our reported gross sales are actually anticipated to be 10 share factors larger than at CER, and working revenue development is now anticipated to be 15 share factors larger than at CER. The optimistic foreign money impression on working revenue of 15 share factors is partly offset by a web loss on monetary objects. For 2022, we now count on that monetary objects will quantity to a web lack of round 6.6 billion Danish kroner, primarily reflecting losses related to international change hedging contracts.
Capital expenditure continues to be anticipated to be round 12 billion Danish kroner, which primarily pertains to investments in extra API manufacturing capability at present manufacturing websites. Our free money circulation is now anticipated to be between 54 billion and 59 billion Danish kroner, reflecting the acquisition of Forma Therapeutics. The acquisition closed within the fourth quarter of 2022. That covers the up to date outlook for ’22.
Now, again to you, Lars, for ultimate remarks.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Thanks, Karsten. Please flip to the ultimate slide. We’re very happy with the double-digit gross sales development within the first 9 months of 2022 and that we proceed to achieve much more sufferers. The robust monetary efficiency within the first 9 months of 2022 has enabled us to lift our outlook for the complete yr.
From an R&D perspective, now we have now efficiently accomplished the complete onboard program with once-weekly insulin icodec, the complete outcomes underlying our dedication to additional elevating the innovation bar in diabetes. We sit up for submitting insulin icodec for regulatory approval within the first half of 2023. As well as, we’re enthusiastic about initiating the part 3 program for CagriSema in weight problems. This might additional strengthen our portfolio of superior weight problems merchandise.
With that, we are actually prepared for the Q&A. We kindly ask all contributors to restrict her or himself to at least one or most of two questions. Operator, we are actually prepared for the primary query.
Questions & Solutions:
Operator
[Operator instructions] We’ll now take the primary query. It comes from the road of Wimal Kapadia from Bernstein. Please go forward. Your line is open.
Wimal Kapadia — AllianceBernstein — Analyst
Properly, nice. Thanks very a lot for taking my questions, please. Really, I will skip, we’re going provide, if that is OK, and begin with the oral weekly semaglutide. Now, this sounds fairly fascinating.
So, my query actually is, is that this only a reformulation of Rybelsus? Will or not it’s for diabetes and weight problems? Does it use a SNAC know-how? What preclinical work have you ever seen to recommend the GI tox could be acceptable? And are you actually attempting to attain injectable-like consequence? So, I do know there’s a couple of bits to that query, however possibly a abstract of that asset could be fairly useful. After which, my second query, simply to Novo’s touch upon sufficient provide of Ozempic to take care of the present trajectory. I assume my query actually is how a lot of the present trajectory is definitely being pushed by lack of Wegovy provide, i.e., weight problems? So, considered one of your friends yesterday, Lilly, urged, you already know, one-third of their Mounjaro sufferers weren’t on diabetes medicines previous to taking the drug. So, except they’re utilizing the drug pre-metformin, that quantity is one-third.
So, I assume what’s that quantity for Ozempic? Thanks.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Thanks, Wimal. First, Martin, on the thrilling prospects of all weekly SMA.
Martin Holst Lange — Govt Vice President and Head of Growth
Sure. Completely. So, you are clearly proper. We’re very enthusiastic about this.
That is an providing that’s, as you rightly level out, Wimal, it is based mostly on our SNAC know-how. It is a bit greater than a reformulation, however we do count on it to permit for a full providing of once-weekly dosing. Our intent is that this could be obtainable probably in each diabetes and weight problems and with an efficacy and security profile much like that of injectables. So, I believe I heard you talked about GI tolerability.
This could be on par with what we have already seen in our subcutaneous semaglutide profiles.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Yeah. Thanks, Martin. An thrilling alternative underlying all capabilities. Then, Karsten, we added some caveats on potential development and linked to provides for subsequent yr.
So, can you set some feedback on that?
Karsten Munk Knudsen — Chief Monetary Officer
Yeah. So, as we put it into our firm announcement, then we’re stating that as we’re significantly increasing our provide capability, then we count on to have sufficient capability to help a possible continuation of the present gross sales development trajectory. So, that is nothing on Ozempic isolation however this can be a macro assertion for nearly all gross sales development and provide capability. So, simply to make clear that.
As to supply of enterprise on Ozempic and the learn throughout you alluded to, then after we’re supply of enterprise on Ozempic, our estimate is that to the tune — within the U.S. market, to the tune of 40% of latest Ozempic enterprise comes from naive sufferers who haven’t obtained their diabetes remedy earlier than.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Thanks, Karsten. And thanks, Wimal. Subsequent query, please.
Operator
Thanks. We’ll now take the subsequent query. It comes from the road of Matthew Weston from Credit score Suisse. Please go forward.
Your line is open.
Matt Weston — Credit score Suisse — Analyst
Thanks very a lot. Can I ask two questions, please? The primary coming again to Wimal and Ozempic capability. Can I perceive the cadence of capability will increase into ’23, please? Is there a selected bolus coming on-line? Or is it very a lot gradual? And to attempt to put into perspective your feedback in regards to the present trajectory, do you consider you’ll have capability to ship consensus gross sales expectations for ’23? After which secondly, a query about U.S. healthcare reform.
We’re getting near the abolition of the Medicaid penny rule cap in January 2024. Ought to we assume that Novo will withdraw penny rule merchandise from the U.S. throughout subsequent yr? Do it’s important to withdraw that product in its entirety, you possibly can’t simply step away from Medicaid? And if that’s the case, are you able to redirect that quantity to different markets? Or can you utilize the fill-finish infrastructure for GLP-1?
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Thanks for these questions. So, on Ozempic, you should not count on. That is form of a one-off occasion that triggers a step change. So, it is a gradual enlargement of capability.
And I will not go in and touch upon our skill to produce towards consensus. We’ll give our steerage for ’23 on the full yr. After which, Doug, on U.S. healthcare reform and Medicaid adjustments developing.
I assume that we can’t be actually detailed on what our plans are. However what are you able to share?
Doug Langa — Govt Vice President, Head of North America Operations
Sure, I believe the query particularly was on the MCAP repeal going into 2024. And definitely, we’re engaged on the potential mitigating actions, however I would not need to get into the specifics.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Yeah. Thanks. Subsequent query, please.
Operator
Thanks. We’ll now take the subsequent query. It comes from the road of Michael Nedelcovych from Cowen. Please go forward.
Your line is open.
Mike Nedelcovych — Cowen and Firm — Analyst
Thanks for the query. So, as has been talked about, many individuals are actually taking different incretins for weight reduction whereas Wegovy provide constrained. It could appear that switching these folks over to the Wegovy, as soon as it is obtainable, may very well be sophisticated. After which, the timing of generic Saxenda availability provides additional complexity.
But, buyers appear to be anticipating the tempo of gross sales of Wegovy, as soon as provide is offered, to recapitulate its preliminary launch trajectory. I am questioning how you consider these elements? And would you advise us to mood our expectations in any respect? After which, my second query is, yesterday, Lilly appeared to indicate {that a} weight reduction drug with efficacy in obesity-associated situations, reminiscent of sleep apnea and coronary heart failure, might need a path to Medicare reimbursement with out the passage of latest laws within the U.S. I do not consider that is Novo’s view. However why is that not an inexpensive assumption? Thanks.
Lars Fruergaard Jorgensen — President and Chief Govt Officer
So, I will begin with a little bit of perspective on useable incretins. After which, possibly, Doug, you possibly can discuss a bit to what we count on after we come again to the U.S. and launch and, maybe, what it takes to get an weight problems product reimbursed within the public account. So, you talked about that there is useable incretins now that Wegovy is brief on provide.
I might really say that almost all uptake is on our personal Saxenda. We’ve seen Saxenda doing actually, very well, a step change and an uptake as we sadly needed to decelerate the launch curve. So, that basically proves that the weight problems market is opening up. So, earlier than that, Wegovy actually created the thrill about what weight reduction potential is feasible.
We noticed a a lot decrease uptake of Saxenda. So, we’re happy with what we see, and we consider that we will each [Technical Difficulty]
Length: 0 minutes
Name contributors:
Lars Fruergaard Jorgensen — President and Chief Govt Officer
Camilla Sylvest — Govt Vice President, Head of Industrial Technique and Company Affairs
Doug Langa — Govt Vice President, Head of North America Operations
Martin Holst Lange — Govt Vice President and Head of Growth
Karsten Munk Knudsen — Chief Monetary Officer
Wimal Kapadia — AllianceBernstein — Analyst
Matt Weston — Credit score Suisse — Analyst
Mike Nedelcovych — Cowen and Firm — Analyst
Extra NVO evaluation
All earnings name transcripts
